Intended for EU healthcare professionals only. The information on this website is not country-specific. This is an international disease awareness campaign.
Back
Infographic

Higher levels of hs-CRP are associated with the risk of PsA development in patients with psoriasis1

Based on a study by Eder L et al. presented at ACR 2023.

Download

Published on

07 Jun 2024
Download

Get similar content directly to your inbox.

Never miss an insight. Register your interest and we'll let you know when new articles are published on this topic

*p=0.003, p<0.001 and p=0.004 for patients with arthralgia, obesity (BMI >30) and female patients, respectively.1 

Data were analysed from a prospective cohort of 589 patients with psoriasis without PsA at enrollment from 2006–2019. hs-CRP values were measured at baseline using standard commercial assays in a hospital laboratory. All patients (n=589) had hs-CRP measurements at baseline; n=35 received biologic therapy at baseline; n=272 had nail lesions at baseline. Patients were assessed annually by a rheumatologist for signs and symptoms of PsA.1 

BMI: body mass index; hs-CRP: high-sensitivity C-reactive protein; PsA: psoriatic arthritis; SD: standard deviation. 

1. Eder L et al. Arthritis Rheumatol. 2023;75(suppl 9). Abstract 0484. 2. Gottlieb AB, Merola JF. J Dermatolog Treat. 2022;33(4):1907–1915.